Advertisement
Advertisement
U.S. markets close in 1 hour 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.68-0.15 (-2.57%)
As of 02:04PM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • A
    ARC
    Annexon is selling 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of common stock and accompanying warrants to purchase up to 8,427,508 shares of common stock, at a combined price of $3.871250 per share of common stock and accompanying common warrant and $3.870250 per pre-funded warrant and accompanying common warrant. Each pre-funded warrant will have an exercise price of $0.001 per share of common stock, will be exercisable immediately and will be exercisable until exercised in full. The accompanying common warrants will have an exercise price of $5.806875 per share of common stock, will be immediately exercisable and expire on June 30, 2025. The private placement is expected to close on July 11, 2022
  • A
    ARC
    ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated
    Disease Progression Stabilized in Overall Patient Population Through the Nine-month Study

Rapid Improvement in Clinical Outcome Measures Maintained in Patients with High Baseline Complement Activity Through the Nine-month Study
  • H
    Hope
    I feel so sorry for some people who bought at all time high
  • A
    ARC
    From FierceBiotech news article:

    The company is taking a precision medicine approach to treating the disease by targeting the C1q complex, which is the start of the complement pathway that plays a key role in triggering inflammation and the defense against pathogens as part of innate immunity. The biotech has hypothesized that by stopping the complement cascade before it starts, diseases like Huntington’s can be prevented.

    What’s most exciting for Annexon, however, is that the data seem to confirm the precision medicine approach, which has been the plan all along. Patients who had higher baseline complement activity at the start of the study experienced rapid clinical benefit during the nine-month study period, beginning about six weeks after dosing.
  • A
    ARC
    Several SEC Form 4s filed today
  • A
    ARC
    President & CEO bought shares on Report I saw yesterday:

    See :

    http://archive.fast-edgar.com/20220418/AWZ2O22CZ222BTZZ2L2N2ZZZQK7Q3ZT8Z242
    SEC FORM 4
    archive.fast-edgar.com
  • A
    ARC
    This stock has totally broken down. Is there a reason for this? Does someone know something that’s not been made public ?
  • D
    David
    $MDVL conversation
    $MDVL rated strong buy, price target $8 https://www.nasdaq.com/market-activity/stocks/mdvl/analyst-research Sales grew 118% year over year & it's down 53% $lrmr $annx $lumo $fbrx
    Bullish
  • b
    betasplen
    100% of float held by institutions as of 12/31/2021? There is almost no free float and hence this could be hammered to these extreme negative EV levels by retail giving up due to interest rate hikes and the war. I believe their Phase 2 results for HD will take this right back to the $7s or higher.
    Bullish
  • s
    stocktracker000
    Interesting Play. Shorts have not covered...

    Full P2 data in 2Q2022 based on company PR. Here is the excerpt:

    The Phase 2 trial remains ongoing, and Annexon anticipates reporting full data from all patients enrolled, including data from the three-month follow-up period, in the second quarter of 2022. Pending results from the full dataset, Annexon plans to evaluate the opportunity for a Phase 3 trial of ANX005 in HD patients.

    Good Luck to all and do your due diligence always...
  • Y
    Yahoo Finance Insights
    Annexon is up 10.88% to 8.05
  • B
    Beff Jezos
    Who's ready for $7 tomorrow? Eskeetit
    Bearish
  • r
    roberto d
    support is 8.45.
  • T
    TradeHunt
    Green day today
    Bullish
  • Y
    Yahoo Finance Insights
    Annexon is up 7.18% to 18.06
  • Y
    Yahoo Finance Insights
    Annexon is up 11.02% to 8.91
  • Y
    Yahoo Finance Insights
    Annexon is up 10.87% to 8.31
  • Y
    Yahoo Finance Insights
    Annexon is up 7.37% to 17.34
Advertisement
Advertisement